Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer - OncoDaily Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer / bladder cancer, cancer, event-free survival (EFS), Neal Shore,

Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer

oncodaily.com/insight/sasa...

#BladderCancer #Cancer #EventFreeSurvival #EFS #OncoDaily #Oncology #Pfizer #Sasanlimab